Optogenetic Treatment for Late-Stage Retinitis Pigmentosa Shows Promising Safety and Visual Function in Phase 1/2 Trial

Results from the GS030 PIONEER trial, evaluating GenSight Biologics' optogenetic treatment for late-stage retinitis pigmentosa (RP), have been published in The New England Journal of Medicine. The article reports primary safety findings and exploratory visual function assessments, indicating that the gene therapy, combined with light-stimulating goggles, can achieve measurable visual responses in patients with advanced RP.